Literature DB >> 9350364

Treatment of intrathecal morphine-induced pruritus following caesarean section.

J A Alhashemi1, E T Crosby, W Grodecki, P J Duffy, K A Hull, C Gallant.   

Abstract

PURPOSE: To compare both the efficacy and cost of nalbuphine and diphenhydramine in the treatment of intrathecal morphine-induced pruritus following Caesarean section.
METHODS: Eighty patients, undergoing elective Caesarean section under spinal anaesthesia, were randomized, in a prospective, double-blind trial, to receive either nalbuphine (Group NAL) or diphenhydramine (Group DIP) for the treatment of SAB morphine-induced pruritus. All patients received an intrathecal injection of 10-12 mg hyperbaric bupivacaine 0.75% and 200 micrograms preservative free morphine. Postoperative pruritus was assessed, using a visual analogue scale (VAS), for 24 hr. Pruritus treatment was administered upon patient request and by a nurse blinded to the treatment given. Patients who failed to respond to three doses of the study drug were deemed treatment failures. Patient satisfaction was assessed with a questionnaire given 24 to 48 hr after surgery. Direct drug costs were calculated based on the pharmacy provision costs as of April 1996.
RESULTS: Eighty patients were enrolled and 45 requested treatment for pruritus. Patients treated with NAL (n = 24) were more likely to achieve a VAS score of zero with treatment (83% vs 43%, P < 0.01), had a higher delta VAS following treatment (4 +/- 2 vs 2 +/- 2, P < 0.003), and experienced fewer treatment failures (4% vs 29%, P < 0.04), than those treated with DIP (n = 21). Group NAL patients were also more likely to rate their pruritus treatment as being good to excellent (96% vs 57%, P < 0.004). Direct drug costs were higher for NAL than for DIP ($6.4 +/- 3.1 vs $1.7 +/- 0.7, respectively, P < 0.0001).
CONCLUSION: Nalbuphine is more effective than diphenhydramine in relieving pruritus caused by intrathecal morphine and the cost differences are small.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9350364     DOI: 10.1007/BF03019227

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  8 in total

Review 1.  Nerve blocks or no nerve blocks for pain control after elective hip replacement (arthroplasty) surgery in adults.

Authors:  Joanne Guay; Rebecca L Johnson; Sandra Kopp
Journal:  Cochrane Database Syst Rev       Date:  2017-10-31

2.  Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis.

Authors:  Saadet Inan; Alvaro Torres-Huerta; Liselotte E Jensen; Nae J Dun; Alan Cowan
Journal:  Eur J Pharmacol       Date:  2019-09-27       Impact factor: 4.432

Review 3.  Neuraxial opioid-induced itch and its pharmacological antagonism.

Authors:  Mei-Chuan Ko
Journal:  Handb Exp Pharmacol       Date:  2015

4.  Antipruritic Effects of Kappa Opioid Receptor Agonists: Evidence from Rodents to Humans.

Authors:  Saadet Inan; Alan Cowan
Journal:  Handb Exp Pharmacol       Date:  2022

Review 5.  Pathophysiology and management of opioid-induced pruritus.

Authors:  Arjunan Ganesh; Lynne G Maxwell
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  Side Effects and Efficacy of Neuraxial Opioids in Pregnant Patients at Delivery: A Comprehensive Review.

Authors:  Sarah Armstrong; Roshan Fernando
Journal:  Drug Saf       Date:  2016-05       Impact factor: 5.606

7.  Comparative study between nalbuphine and ondansetron in prevention of intrathecal morphine-induced pruritus in women undergoing cesarean section.

Authors:  Ahmed A M Moustafa; Amr Samir Baaror; Ibrahim A Abdelazim
Journal:  Anesth Essays Res       Date:  2016 May-Aug

8.  Evaluation of Efficacy of Mirtazapine on Pruritus and Serum Histamine and Serotonin Levels in Patients Undergoing Hemodialysis: A Before-After Pilot Clinical Trial.

Authors:  Maryam Mehrpooya; Mahmoud Gholyaf; Fatemeh Yasrebifar; Younes Mohammadi; Vida Sheikh
Journal:  Int J Nephrol Renovasc Dis       Date:  2020-05-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.